Osteoclasts are the body’s sole bone resorbing cells. Cytokines produced by pro-inflammatory effector T-cells (TEFF) increase bone resorption by osteoclasts. Prolonged exposure to the TEFF produced cytokines leads to bone erosion diseases such as osteoporosis and rheumatoid arthritis. The crosstalk between T-cells and osteoclasts has been termed osteoimmunology. We have previously shown that under non-inflammatory conditions, murine osteoclasts can recruit naïve CD8 T-cells and activate these T-cells to induce CD25 and FoxP3 (TcREG). The activation of CD8 T-cells by osteoclasts also induced the cytokines IL-2, IL-6, IL-10 and IFN-γ. Individually, these cytokines can activate or suppress osteoclast resorption.
To determine the net effect of TcREG on osteoclast activity we used a number of in vitro assays. We found that TcREG can potently and directly suppress bone resorption by osteoclasts. TcREG could suppress osteoclast differentiation and resorption by mature osteoclasts, but did not affect their survival. Additionally, we showed that TcREG suppress cytoskeletal reorganization in mature osteoclasts. Whereas induction of TcREG by osteoclasts is antigen-dependent, suppression of osteoclasts by TcREG does not require antigen or re-stimulation. We demonstrated that antibody blockade of IL-6, IL-10 or IFN-γ relieved suppression. The suppression did not require direct contact between the TcREG and osteoclasts.
We have determined that osteoclast-induced TcREG can suppress osteoclast activity, forming a negative feedback system. As the CD8 T-cells are activated in the absence of inflammatory signals, these observations suggest that this regulatory loop may play a role in regulating skeletal homeostasis. Our results provide the first documentation of suppression of osteoclast activity by CD8 regulatory T-cells and thus, extend the purview of osteoimmunology.
Citation: Buchwald ZS, Kiesel JR, DiPaolo R, Pagadala MS, Aurora R (2012) Osteoclast Activated FoxP3+ CD8+ T-Cells Suppress Bone Resorption in vitro. PLoS ONE 7(6): e38199. doi:10.1371/journal.pone.0038199
Editor: Ivan Cruz Moura, Institut national de la santé et de la recherche médicale (INSERM), France
Received: November 23, 2011; Accepted: May 3, 2012; Published: June 6, 2012
Copyright: © 2012 Buchwald et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: No current external funding sources for this study.
Competing interests: The authors have declared that no competing interests exist.
The skeletal system is dynamically and constantly remodeled throughout life to maintain bone integrity. There are multiple layers of regulation imposed on the skeletal system homeostasis, including physiological levels of phosphate, calcium, hormones, mechanical loading (e.g. Wolff’s law) and energy metabolism (reviewed in ). Two cells play a key role in remodeling bone: osteoclasts and osteoblasts. Osteoclasts are large multinucleated cells that are the principal, if not sole, bone resorbing cells in the body. Osteoclasts are derived from the myeloid lineage and therefore may be considered a specialized immune cell. Balancing the function of the osteoclasts are osteoblasts, of mesenchymal origin, which form new bone. Osteoblasts also provide essential signals for, and regulate the differentiation of, the myeloid lineage osteoclast precursors by producing macrophage colony-stimulating factor (M-CSF), receptor activator of NF-κB ligand (RANKL; Tnfsf11) and other co-stimulatory factors in the bone marrow , , , .
It has been recognized in the last decade that skeletal homeostasis is dynamically influenced by the immune system. This emerging field, called osteoimmunology , arose from observations demonstrating that lymphocyte-derived cytokines, including RANKL, interleukin (IL)-17 and type I and II interferons, are potent mediators of osteoclast function and osteoclastogenesis , , , , , , . Osteoclast activity and numbers are increased by cytokines produced by effector T-cells leading to bone erosion in inflammatory diseases such as rheumatoid arthritis and periodontitis. T-cell produced cytokines also play a critical role in bone cancers, post-menopausal osteoporosis and in Paget’s disease , , , .
The immune system also maintains two counterbalancing cell types: the effectors (e.g. TH17), which are dominant during the inflammatory phase, and the regulatory T-cells (TREG). The transcription factor FoxP3 is a marker of TREG that have the ability to suppress aberrant activation of self-reactive lymphocytes. Loss of FoxP3 function results in fatal autoimmune pathology affecting multiple organs in both humans and mice , , , . Adoptive transfer of T-cells expressing FoxP3 into mice with FoxP3 loss-of-function abolishes the autoimmune pathology , , , . Regulatory T-cells that express FoxP3 also express CD25, the α-chain of the IL-2 receptor. The transfer of CD4 T-cells depleted of the CD25+ fraction (∼10%) from a normal adult mouse into a mouse lacking an intact immune system produces autoimmune disease . Conversely, transfer of the CD25+ CD4 T-cells from normal mice into T-cell–deficient mice suppressed allergy and prevented graft-versus-host disease after bone marrow transplantation . TREG mediate their regulatory function through a number of mechanisms. First, TREG express anti-inflammatory cytokines including IL-10, TGFβ and IL-35 , , , . Another mechanism of regulation is by cell-cell contact: cytotoxic T-lymphocyte antigen-4 (CTLA-4) expressed on TREG binds with ∼10 fold higher affinity to co-stimulatory B7 molecules on antigen presenting cells (APC) than CD28, and thus prevent APC from activating naïve T-cells . TREG have also been proposed to prevent differentiation of effector T-cells by consuming IL-2, IL-4 and IL-7 required for T-cell activation and polarization .
Compared to CD4 TREG, the FoxP3+ CD8 T-cells (referred to as TcREG here) have not been extensively studied due in part to their low abundance in lymphoid tissue, and the ability of CD4 TREG to regulate activation of both CD4 and CD8 T-cells , , , . While a few recent studies have indicated that TcREG may also regulate the immune system , , , their physiological role in immune regulation has not been definitively established. Other regulatory CD8 T-cells that do not express FoxP3 have also been observed and studied .
Here we examined the interaction between osteoclasts and TcREG. We uncovered the osteoclast–CD8 T-cell interaction using a time-series microarray dataset to study osteoclastogenesis. Our data showed that RANKL treatment of bone marrow monocytes coordinately induced a number of chemokines and MHC class I presentation pathway during differentiation . In follow up experiments, we showed that the osteoclast-secreted chemokines preferentially recruited CD8 T-cells. Cross-presentation (i.e. presentation of peptides from extracellular proteins on MHC class I) of antigens to CD8 T-cells induced IFN-γ, IL-6 and IL-2 only in the presence of antigen. Antigen presentation by osteoclasts has also been subsequently demonstrated for human osteoclasts derived from peripheral blood mononuclear cells . The priming of naïve CD8 T-cells by osteoclasts induced FoxP3, CD25, CTLA-4, RANKL, and CD122 . The osteoclast-primed FoxP3+ CD8 T-cells were able to suppress proliferation of naïve responder CD8 T-cells by DCs and thus have a potential regulatory T-cell activity . Interestingly, the TcREG express IFN-γ and CTLA-4, which inhibit osteoclast activity , , , , , , while RANKL increases osteoclast activity. IL-6 directly inhibits osteoclast activity but can induce RANKL expression in osteoblasts to increase osteoclast function , . Thus, these T-cell produced cytokines could potentially activate or suppress osteoclast activity. We therefore tested if TcREG could regulate osteoclast resorption activity.
Induction of TcREG by Mature Osteoclasts is Antigen-dependent
We first show (Fig. 1A) that mature osteoclasts can induce FoxP3 and CD25 in ovalbumin (OVA)-specific OT-I CD8 T-cells only in the presence of antigen. The induction of FoxP3 in the presence of antigen was assayed by both multicolor flow cytometry (top panels) and by reverse transcription (RT) of RNA isolated from the co-culture, followed by PCR (middle panel). As controls, we isolated RNA from purified GFP positive and negative CD4 and CD8 T-cells from the transgenic FoxP3eGFP reporter mouse , . These reporter mice co-express the enhanced green fluorescent protein (eGFP) and transcription factor FoxP3 under control of the endogenous promoter. We show that only mature osteoclasts (incubated in the presence of RANKL for 4 days) have the ability to induce FoxP3 as the osteoclast precursors (bone marrow derived monocytes) could not induce the regulatory phenotype in CD8 T-cells.
TGFβ1 can induce regulatory T-cells in the periphery and in vitro , , , . Avian osteoclasts have been reported to express the latent form of TGFβ . To assess if murine osteoclasts express TGFβ that could induce TcREG, we measured the expression of TGFβ by quantitative real-time PCR (qRT-PCR). The relative expression (2ΔΔCt with respect to β-actin) of TGFβ1 in osteoclasts (+M-CSF, +RANKL) over osteoclast precursors (+MCSF, -RANKL) was determined to be 5.5±0.8 fold. The relative expression decreased to 0.9±0.6 fold (about the same as in the precursors) in the presence of TcREG, indicating that TcREG suppress TGFβ expression by osteoclasts. However, these results do not address the role of TGFβ in TcREG induction. Furthermore, as bone contains significant levels of TGFβ that is released by the action of osteoclasts , , , , and the effect of TGFβ can be dose-dependent, we added increasing amounts of TGFβ to the osteoclast and OT-I co-cultures to test its effect on the induction of TcREG. While adding an antibody that neutralizes all three forms of TGFβ at 50 µg/ml efficiently blocked the induction of CD4 TREG, the antibody had no effect, at any dose tested, on the numbers of TcREG induced (Fig. 1B left). Addition of recombinant murine TGFβ1 also had no statistically significant effect on the induction of TcREG by osteoclasts at any concentration of TGFβ tested (Fig. 1B right). Taken together these results indicate that while osteoclasts express TGFβ1, the cytokine is not required for induction of TcREG by osteoclasts; furthermore, in the presence of TcREG, TGFβ1 mRNA levels decreased in osteoclasts.
Consistent with our previous observations , the induction of FoxP3 coincides with production of the cytokines IFN-γ, IL-6, IL-10, again only in the presence of OVA (Fig. 1C top). All of the cytokines measured by ELISA were found to be expressed by the CD8 T-cells as measured by intracellular staining and flow cytometry and not by osteoclasts (Fig. 1C bottom). These results show that only mature osteoclasts have the ability to induce CD25, FoxP3 and the cytokines IFN-γ, IL-6 and IL-10 in T-cells in an antigen-dependent manner. Finally, we did not detect any change in the levels of CD80, MHC class I surface expression, or detectable levels of MHC class II, on the osteoclasts after 48 hour of co-culture with CD8 T-cells or TcREG (data not shown).
TcREG Suppress Osteoclast Resorption Activity in vitro
To directly test if osteoclast-induced TcREG affect resorption activity, we co-cultured purified ovalbumin-specific transgenic OT-I TcREG with osteoclasts (1∶1 ratio). The osteoclasts were grown on hydroxyapatite-coated slides or wells to measure resorption activity, rather than bone slices to avoid any confounding effects of TGFβ present in the bone. The data is presented as the total area resorbed and the number of pits in the presence of T-cells relative to osteoclast only cultures. The co-cultures were performed with either “in-situ” produced TcREG, or TcREG induced by osteoclasts plated on tissue-culture plates, then transferred to osteoclasts growing on hydroxyapatite-coated slides.
Mature osteoclasts (day 4) or osteoclast precursors were cultured with no Ag or OVA protein and then used to prime CD8 T-cells from an OT-I mouse. A. T-cells were collected at 48 h following initiation of co-culture. T-cells were stained for CD44, CD25 and FoxP3 and then analyzed by flow cytometry. T-cells co-cultured with osteoclasts in the absence of antigen do not express FoxP3+ or CD25 (top); FoxP3 and CD25 were induced in the presence of antigen as shown in the representative flow plot. The expression of FoxP3 was confirmed by reverse-transcription of RNA isolated from the co-culture and subsequent PCR of cDNA. GFP sorted cells from FoxP3eGFP reporter mice were used as controls. Only mature (day 4) osteoclasts supported the generation of TcREG (right panel). B. Anti-mouse TGFβ was added to co-cultures at the dose indicated (left). Addition of recombinant murine TGFβ1 to co-cultures of CD8 T-cells and osteoclasts at concentration indicated (right). The percent of input T-cells converted to FoxP3+ are plotted in both panels. No statistically significant effect was observed on TcREG induction with either the addition of neutralizing antibody or recombinant TGFβ. C. Media was collected and cytokine quantitated by multiplexed ELISA. After 48 h of co-culture, cells were treated with Golgi stop and PMA plus ionomycin for 6 h. The cells were permeabilized, stained and evaluated for cytokine production by flow cytometry. While the CD11b+ osteoclasts were negative for all cytokines, the CD8+ T-cells stained triple positive for IL-10, IL-6, and IFN-γ. Statistical significance was assessed by non-parametric paired T test: *: P<0.05, **: P<0.01, ***: P<0.001 and ****: P<0.0001.
Our results (Fig. 2A, B) show that the in situ produced TcREG suppressed osteoclast resorption activity. We also tested TGFβ-induced OT-II (CD4) TREG (iTREG) in the co-culture assay. Whereas, in the presence of the induced OT-II TREG osteoclast resorption activity modestly increased (1.5-fold in area resorbed), re-stimulation of the TREG with anti-CD3 + anti-CD28 was required to observe suppression. In contrast, the osteoclast-induced TcREG could suppress in the absence of re-stimulation. We also tested if CD8 T-cells when activated by anti-CD3 and anti-CD28 in the presence of IL-2 could suppress resorption by osteoclasts. While CD8 T-cells activated in this manner produce significant levels of IFN-γ, they were only able to partially suppress (∼25% suppression) pitting by osteoclasts. Finally, we tested if in vivo generated TcREG could suppress osteoclast activity. TcREG were purified from the bone marrow space by cell sorting to >95% purity, then co-cultured with osteoclasts (at a ratio of 3 osteoclasts to 1 GFP+ T-cell) on hydroxyapatite-coated plates. The CD8+ GFP+ TcREG population was able to efficiently suppress osteoclast resorption activity, whereas the CD8+ GFP− population did not (Fig. 2B).
A. Osteoclasts (day 3) lifted and plated on hydroxyapatite-coated plates. OT-I TcREG or OT-II TGFβ-induced FoxP3+ CD4 T-cells (iTREG) generated in separate dishes were added next day. The co-cultures were re-fed every two days. After seven days, the wells were treated with bleach, photographed, and total pit area was quantified (results in panel B). Representative images from five replicates are shown in panel A. No pitting was observed in the presence of TcREG (top right). Larger pits were observed in the presence of iTREG (bottom left), but TcREG were dominant suppressors (bottom right). B. TcREG suppressed pitting on hydroxyapatite plates without re-stimulation. In contrast, iTREG could only suppress after re-stimulation (see methods for details). IFN-γ producing OT-I T-cells activated by anti-CD3 and anti-CD28 in the presence of IL-2 could partially suppress pitting by osteoclasts. Activated GFP+ CD8 T-cells purified by cell sorting from FoxP3eGFP reporter mice could also suppress osteoclast pitting, while conventional (GFP−) CD8 had no affect on pitting. Statistical significance of area resorbed was assessed by Wilcoxon test: *: P<0.05, **: P<0.01 and ***: P<0.001 relative to osteoclast alone wells.
Our results show that the osteoclast-induced TcREG, whether produced by co-culture, or isolated from a mouse, have the ability to suppress osteoclast activity. In experiments shown below, we address the mechanism by which the TcREG mediate this suppression of osteoclasts.
TcREG Suppress Osteoclast Differentiation but not Survival
IFN-γ blocks osteoclast differentiation, while RANKL promotes differentiation and survival of the osteoclasts. As the pitting assays described above require 7 to 10 days, one mechanism by which TcREG could mediate a loss of pitting would be to suppress osteoclast differentiation. To test for the effect of TcREG on osteoclastogenesis, we cultured bone marrow cells with M-CSF for three days, and then removed non-adherent cells to enrich for osteoclast precursors; RANKL was then added with TcREG (generated on independent wells with mature osteoclasts). After four days of co-culturing we visualized and enumerated the osteoclasts using the fluorescent substrate ELF-97 for tartrate resistant acid phosphatase (TRAP), a marker of osteoclasts . The results show that no TRAP positive cells were induced by RANKL (top middle panel Fig. 3A) in the presence of TcREG. In contrast, many large TRAP positive osteoclasts were observed in the absence of T-cells (top left), and in the presence of naïve CD8 T-cells (upper right). Sato et al.  have previously shown that TGFβ-induced TREG cannot suppress osteoclastogenesis, where as Zaiss et al.  obtained the opposite results. Our results (Fig. 3A) show that iTREG cannot suppress osteoclastogenesis unless they are restimulated with anti-CD3 and anti-CD28. To test if IFN-γ is solely responsible for suppression of osteoclast differentiation, we used bone marrow from IFN-γ receptor knockout (IFNγR1−/−) mice. We found that TcREG could efficiently suppress osteoclast differentiation of IFNγR1−/− precursors, indicating that additional cytokines play a role in mediating suppression of osteoclastogenesis. Finally, we confirmed the suppression using quantitative real-time PCR of three osteoclast markers (Fig. 3A bottom right). These marker genes were chosen because they are expressed in mature osteoclasts and absent in T-cells.
A. Osteoclast precursor cells (day 0) were cultured alone, with pre-differentiated TcREG, iTREG, anti-mouse CD3/CD28 re-stimulated iTREG, or with naïve T-cells in the presence of GST-RANKL. After four days, non-adherent cells were removed by aspiration and remaining cells were stained with a fluorescent TRAP substrate ELF-97. Representative images from four experiments are shown in top panel, and quantitated cells counts are shown below. To test if suppression of osteoclastogenesis was mediated solely by IFN-γ, bone marrow cells from IFNγR1−/− mice were used. The results of TRAP staining were confirmed by quantitative real-time PCR using primers for Acp5 (TRAP), Cathepsin K (CTSK) and matrix metalloprotease-9 (MMP-9). β-actin expression was used for normalization. B. Osteoclasts, cultured in the absence or presence of TcREG for five days were counted after TRAP staining with ELF-97. To test for increased apoptosis adherent cells were stained with Annexin V. Each data point is average of three wells per experiment. Statistical significance was assessed by non-parametric paired T test: *: P<0.05, **: P<0.01 and ***: P<0.001 by comparison to untreated (Untx) osteoclast wells.
Next, we considered if TcREG could control osteoclast numbers, and hence function, by regulating their survival or lifespan. For instance, IFN-γ can induce Fas ligand expression in osteoclasts, in the presence of TNFα to induce apoptosis . In other cell types, TGFβ and IL-18 have been shown to induce Fas ligand , . As a measure of the effect of TcREG on osteoclast survival, we used the numbers of TRAP and Annexin-V positive osteoclast after five days of co-culturing. The results show that TcREG do not decrease the survival of osteoclasts, as there was a slight increase in the number of osteoclasts (Fig. 3B left panel), and a slight decrease in the number of Annexin-V positive osteoclasts (Fig. 3B right panel) in the presence of TcREG. The results of these experiments indicate that TcREG suppress the differentiation of the osteoclasts but do not significantly affect their survival.
TcREG Suppress Mature Osteoclasts by Preventing Cytoskeletal Reorganization
Osteoclasts must adhere to the bone surface and migrate along it to resorb ; cytoskeletal reorganization is critical for this process , . Therefore, we stained for actin rings in osteoclasts in the presence and absence of TcREG. TcREG were cultured with mature osteoclasts seeded on bone, or on plastic for 24 h. T-cells were then removed and the actin rings were visualized using flour-conjugated phalloidin. In the presence of TcREG, the actin ring was either eliminated on bone (Fig. 4A and B), or (the actin belt) was reduced in size on plastic (Fig. 4C).
Osteoclasts were cultured either alone or with TcREG on bovine bone chips for 24 hrs. T-cells were then removed, and osteoclasts were stained with phalloidin-Texas Red to visualize actin rings. Representative images are shown in panel A. Quantitation of three independent experiments is shown in panel B. Panel C is quantitation of phalloidin staining of osteoclasts plated on tissue culture treated dishes. Statistical significance of actin ring area was assessed by non-parametric paired T test: **: P<0.01 in comparison to osteoclast alone.
These results indicate that TcREG can act directly on mature osteoclasts and prevent the formation of sealing zones. Our data indicates that TcREG and restimulated iTREG can efficiently block osteoclastogenesis, but not their survival. As osteoclasts express MHC class I but not class II  it is possible that co-culturing TcREG in the pitting assay with the osteoclasts re-stimulates the TcREG but not the iTREG. Therefore, in the next set of experiments we tested if suppression of osteoclast activity requires antigen presentation by osteoclasts. We also tested if direct cell contact between TcREG and osteoclasts is needed to mediate suppression.
Suppression of Osteoclasts Activity is Mediated by TcREG Secreted Cytokines
To test if the regulation of osteoclast activity was antigen-dependent, OT-I FoxP3+ T-cells were cultured with osteoclasts in the presence or absence of OVA peptide. As shown in Fig. 5A, TcREG could suppress osteoclasts to similar levels in the presence or absence of antigen presentation. Therefore, we next tested if direct contact between osteoclasts and TcREG was required to mediate suppression. TcREG were able to suppress osteoclast activity to a significant level when separated by a membrane with a 0.45 μ pore (Fig. 5B). These results indicated that the secreted cytokines were, to a large extent, responsible for the suppressive activity.
A. Osteoclasts were seeded on hydroxyapatite-coated plates and allowed to adhere overnight. The osteoclasts were pulsed with SIINFEKL peptide (+Antigen) or a control FLAG peptide (-Antigen). OT-I TcREG or naïve CD8 T-cells were added and co-cultured for 7 days. Cells were re-fed with medium containing M-CSF and RANKL every 2 to 3 days. The plates were then treated with bleach solution, washed, dried and photographed. Representative photomicrographs are shown on the left. Quantitation from four experiments of three wells each is shown on the left. B. TcREG were added to top-insert of transwell (0.45-µ membrane) separated from the osteoclast plated on 24-well Corning Osteo-Assay plate. Osteoclast activity was determined by quantifying total pit area resorbed following 10 days of co-incubation. C. In a culture of both osteoclast and TcREG on Corning Osteo-Assay plates, neutralizing antibodies against IL-10 (25 µg/ml), IFN-γ (50 µg/ml), IL-6 (20 µg/ml) or CTLA-4 (10 µg/ml) were added to determine their impact on osteoclast activity. The cells were co-cultured for 10 additional days, and re-fed with media containing M-CSF, RANKL every three days. Re-feed media with antibodies were added on days 3 and 6. D. Pitting assay as described in Panel C were conducted in parallel using osteoclasts from either wild type (WT) or IFNγR1−/− mice. Statistical significance of area resorbed was assessed by non-parametric paired T test: *: P<0.05, **: P<0.01 and ***: P<0.001 in comparison to osteoclast alone wells.
To identify the specific cytokines responsible for osteoclast suppression, pre-differentiated TcREG were incubated with mature osteoclasts in the presence of neutralizing antibodies. Blockade of IFN-γ showed the most significant reduction in osteoclast inhibition while neutralizing IL-10 and IL-6 also relieved suppression (Fig. 5C). CTLA-4 blockade showed no effect confirming that the secreted cytokines IL-6, IL-10, and IFN-γ all contribute to osteoclast suppression. Osteoclasts express FC receptors (FcR), and there could be a concern about confounding effects from the added antibody. Although, we used rat anti-mouse antibodies to minimize the likelihood of mouse FcR from binding to the rat antibodies, a possibility remains. Second, the active moiety of some of the cytokines, notably IFN-γ is a dimer  it is possible that immune complex formation could confound the results. To directly address these issues we added duck Hepatitis B virus (dHBV) polymerase to our co-culture, and titrated mouse-anti dHBV polymerase antibody (20 to 70 µg/ml). We observed no effect on suppression (data not shown), indicating that the antibodies, and potential immune complex formation did not confound the assay.
To confirm the results of antibody neutralization we generated osteoclasts from IFNγR1 knockout mice. We found that TcREG generated from OT-I mice could suppress IFNγR1−/−osteoclast pitting to a similar extent as wild-type osteoclasts (Fig. 5D). Taken together, our data document that TcREG, once generated can suppress osteoclast resorption directly through secreted cytokines. Altering the concentration by neutralizing antibody against all secreted cytokines expressed by TcREG relieved suppression, while blockade of TcREG expressed CTLA-4 had no measurable effect of suppression.
Many studies have now established that under inflammatory conditions, T-cell produced cytokines increase osteoclast activity leading to bone erosion , , . This close relationship between the skeletal and immune systems is illustrated in diseases such as autoimmune rheumatoid arthritis and periodontitis. The crosstalk between the immune and skeletal system has been termed osteoimmunology. Osteoimmunology emerged from the early pioneering work of Suda and colleagues (reviewed in ) and the demonstration that RANKL, a critical mediator of osteoclasts, is expressed on T-cells . Here we examined the regulation of osteoclasts by FoxP3+ CD8 T-cells (TcREG). Although TcREG have been documented in humans and mice , , , , , , , , , , , , , , , , they have not been studied extensively, in part due to their low abundance (0.2 to 2% of CD8 T-cells) in lymphoid organs. In comparison, the well-studied CD4 regulatory T-cells, TREG, comprise 5–12% of CD4 T-cell in the spleen. The TcREG and the TREG have overlapping and distinct functions. Both cells express CD25 and the transcription factor, FoxP3 a marker of the regulatory T-cells , , .
Based on the mediator cytokines produced by the TcREG, in this work we examined if the osteoclast induce TcREG could control osteoclast activity. Our results show that the osteoclast-induced TcREG secreted cytokines (Fig. 1) that could suppress resorption by osteoclasts (Fig. 2). Induction of TcREG by osteoclasts required antigen (Fig. 1), through cross presentation by osteoclasts . Once activated, TcREG, unlike the TREG, do not require restimulation to suppress osteoclasts (Fig. 2). To examine the mechanisms by which suppression is mediated, we measured the effect of the TcREG on differentiation of osteoclasts. Our data shows that TcREG and iTREG block osteoclastogenesis (Fig. 3A). The TcREG did not affect the survival of osteoclasts (Fig. 3B), but TcREG could directly act on mature osteoclasts to suppress actin ring formation (and actin belt formation; Fig. 4). To elaborate on the requirement that TcREG do not require restimulation, we showed that TcREG could suppress osteoclast activity in the absence of antigen (Fig. 5A) and when separated from the osteoclasts by a membrane with a 0.45 µ pore (Fig. 5B) indicating the secreted cytokines mediate the suppression. To indentify the cytokine(s), we used neutralizing antibodies against the secreted cytokines and found that altering the levels of any of the three cytokine relieved the suppression of osteoclast activity (Fig. 5C). Indeed, TcREG could effectively suppress pitting of IFNγR1−/− osteoclasts (Fig. 5D). Although the role of TcREG in controlling the immune system is still being defined , our results provide a new physiological role for the TcREG: the inhibition of osteoclast activity under homeostatic conditions.
Regulatory T-cells use a number of mechanisms to suppress the immune system as noted above, however only a subset of the mechanisms may be expressed in a given situation. In this context, we note that the osteoclast-induced TcREG produce IL-6 and IFN-γ, molecules that would normally be considered pro-inflammatory, but previous studies have shown they can affect osteoclast activity . Based on a number of recent studies that demonstrate a remarkable plasticity in TREG responses , , we speculate that this may be a general phenomenon for regulatory T-cells: the method of activation and their location may allow them to express specific effector functions, to regulate cells at hand. This phenomenon may underlie the apparent multiple types of TREG observed , .
Summarizing, we demonstrate that FoxP3+ CD8 T-cells can suppress osteoclast resorptive function and thus provide a novel control function for regulatory T-cells beyond regulation of the immune system. The ability of osteoclasts to induce TcREG and the ability of TcREG to subsequently regulate osteoclast function establishes a bi-directional regulatory loop between these two cells in the bone marrow. Notably, the regulatory loop does not require the presence, in vitro, of pro-inflammatory cytokines. Indeed, our ability to isolate functional TcREG from mice, in the absence of any inflammatory disease (Fig. 2B), indicates that these cells have a role in maintaining skeletal homeostasis in vivo. In contrast to CD4 TREG, the TcREG may have a more specialized and local function. The ability of osteoclasts to induce TcREG and their ability to suppress without restimulation may provide an explanation for the low levels of TcREG found in vivo: the system is rapidly inducible, so a large reservoir of TcREG is not needed. The induction of the TcREG by osteoclasts that suppress osteoclasts would be self-limiting and lead to small number of TcREG. Osteoclasts remodel bone as part of basic multicellular unit (BMU) that includes osteoblasts and other cells , . The rapid induction of TcREG also suggests that the local concentration of the TcREG-produced cytokines is likely to be high, thus requiring a small number of TcREG. This notion is consistent with our observation that TcREG suppressed osteoclast slightly less well when separated in a transwell. Finally, in contrast to CD4 TREG cells, which require MHC class II for activation, regulatory CD8 T-cells can be activated by any MHC class I expressing cells. All cells (except red blood cells) express MHC class I and therefore could activate TcREG, an abundance of TcREG could suppress host response to pathogens.
Why does the immune system regulate osteoclasts? We suggest two possibilities: First, regulatory T-cells have evolved to suppress the immune system. As osteoclasts are derived from myeloid cells, they retain the ability to respond to immune signals. Just as cytokines produced by effector T-cells activate osteoclast activity in inflammatory bone erosion diseases, the cytokines produced by TcREG suppress osteoclasts. In addition to ontogeny, a functional linkage may also exist. The bone marrow is the primary site of hematopoiesis. Stromal cells line, provide essential support and form a specialized sealed compartment (“niche”) for the hematopoetic stem cells (HSC) , , , . It has been documented that osteoclast activity modulates the egress of the hematopoetic precursors (HPC) from the niches , . We hypothesize that the immune system may increase osteoclast activity through production of effector T-cells (TEFF). The TEFF secreted cytokines increase osteoclast activity during inflammation to replenish lost immune cells and thus increase circulating hematopoetic precursors (HPC). To maintain balance or restore homeostasis after inflammation, TcREG may be used to suppress osteoclast activity. For example, it is conceivable that the TcREG evolved to provide an elegant sensor for T-cell lymphopenia. A reduction in TcREG numbers may lead to an increase in bone resorption, and the subsequent increase in HPC mobilization. More studies are needed to explore the consequences of this bidirectional regulation for both the bone and autoimmune regulation, and to identify the sensors that mediate this regulation.
Materials and Methods
Mice: Five-week-old male C57BL/6 mice were purchased from Jackson Labs or used from in-house breeding colony. A breeder trio of FoxP3eGFP reporter mice on a C57BL/6 background were purchased from Jackson Labs, and bred in-house for these experiments. OT-I/Rag−/− and OT-II/Rag−/− mice were purchased from Taconic. All animals were maintained in the Department of Comparative Medicine, Saint Louis University School of Medicine in accordance with institutional and Public Health Service Guidelines. Saint Louis University School of Medicine Institutional Animal Care and Use Committee approved all procedures performed on mice (Protocol 2072). Purchased animals were allowed to acclimate for at least one week, prior to use.
Generation of Osteoclasts
Osteoclast precursors were isolated as previously described , . Briefly, the mice were sacrificed by CO2 asphyxiation and the long bones harvested. The caps of the bones were removed and bone marrow cells were flushed with 0.05% collagenase (Worthington) in α-minimum essential medium (αMEM, Invitrogen). The cell population was filtered through a 40 µ cell strainer, pelleted, resuspended and maintained in αMEM growth medium (αMEM supplemented with 10% heat-inactivated fetal bovine serum [Invitrogen]), penicillin-streptomycin-glutamine (Invitrogen) and recombinant murine M-CSF (Peprotech) at 20 ng/ml). Osteoclasts were generated by addition of recombinant murine GST-RANKL (gift of Steven Teitelbaum, Washington University in St. Louis) to a final concentration of 50 ng/ml. M-CSF and GST-RANKL were added every 48 to 72 h. Cells were harvested by a 15 m treatment with Versene (Gibco).
Isolation of Splenocytes
Single cell suspensions of spleens were prepared in PBS +1% FBS by grinding with a sterile syringe plunger and dispersed by pipetting, then filtering through a 40 µ cell strainer. For co-culture experiments, OT-II CD4 or OT-I CD8 T-cells were prepared by first enriching for T-cells using Pan-T-cell beads then purified by negative selection using appropriate magnetic beads (Miltenyi). The resulting T-cells were routinely >97% pure when stained with anti-CD3, anti-CD4 and anti-CD8 antibody.
Generation of TcREG
Day 3 osteoclasts cultured in 20 ng/ml M-CSF and 50 ng/ml GST-RANKL, were seeded at 5×105 cells/ml/well in the presence of 5 µM OVA (A-5503; Sigma-Aldrich) in 24-well tissue culture-treated plates (Corning). After overnight incubation, medium was removed and (adherent) cells were washed with pre-warmed (37°C) medium. 2.5×105 freshly harvested splenic OT-I transgenic T cells purified by negative selection were added in 2 mls of complete T-cell media (RPMI, 10% heat-inactivated FBS (ΔFBS; HyClone), penicillin-streptomycin-glutamine (HyClone), non-essential amino acids, sodium pyruvate, HEPES, and 55 µM β-mercaptoethanol. Following 48 h co-culture, T-cell aliquots were removed and stained intracellularly to assay for FoxP3 expression. TGFβ -induced TREG were generated as previously described . Briefly, CD4 T-cells were purified from an OT-II spleen by magnetic beads, and stimulated with plate-bound anti-CD3 (1 µg/ml) and anti-CD28 (2 µg/ml) in the presence of IL-2 and rhTGF-β1 (5 ng/ml). After 48 h of stimulation, the cells were expanded in IL-2 (100 U/ml) containing media for 48 hours. The iTREG were used directly, or in some experiments, restimulated with plate bound anti-CD3/anti-CD28 (as above) for an additional 48 hours in the absence of rhTGFβ.
Antibodies and Fluorescence Activated Cells Sorting (FACS)
Anti-mouse antibodies for FACS were: PE-conjugated anti-mouse CD8a (clone 53-6.7; BD Pharmingen), AF700-conjugated anti-mouse CD44 (clone IM7; BD Pharmingen), e450-conjugated anti-mouse FoxP3 (clone FJK-16s, eBioscience), APC-conjugated anti-mouse IFN-γ (XMG1.2, eBioscience), FITC-conjugated anti-mouse IL-10 (JES5-16E3, eBioscience) and FITC-conjugated anti-mouse IL-6 (MP5-20F3, eBioscience), and PE-Cy7-conjugated anti-mouse CD11b (M1/70, eBioscience). Cells were blocked with anti-mouse FcgRIII/IIR (BD Pharmingen) for 10 m and then stained for 45 m on ice with fluorophore-conjugated antibody. Stained cells were pelleted, washed, fixed with 3% paraformaldehyde and analyzed on LSR instrument with CellQuest (BD Biosciences) software. FACS data analyses were performed with FlowJo (Tree Star).
Abs for cytokine neutralization were: anti-mouse IL-10 (clone JES5-2A5, eBioscience), anti-mouse IFN-γ (clone R4-6A2, eBiosciences), anti-mouse IL-6 (clone MP5-20F3, eBiosciences), clone 1D11.16  that recognizes all three forms of mammalian TGFβ, and anti-mouse CTLA-4 (clone 63828, R&D Systems).
Cytokine Profiling by Multiplexed ELISA
Cytokine quantitation (IL-6, IL10, and IFN-γ) was performed using multiplexed ELISA (Millipore/Linco Research) per the vendor’s protocol on a Luminex-100. The data was analyzed using three-point logistic fitting in Microsoft Excel.
For osteoclast staining, Golgi Stop (BD Biosciences) was added to T-cell/osteoclast co-cultures at 4 µl/(6×106) cells and incubated for 6 h. Osteoclasts were collected using ice-cold PBS and vigorous pipetting. For T-cell staining, 50 ng/ml phorbol 12-myristate 13-acetate and 1 µg/ml ionomycin were added to T-cell/osteoclast cultures for initial 1 h incubation. Golgi Stop (Invitrogen) was then added, and cultured for 3 h. T-cells were then removed from the plate using pre-warmed PBS. Cells were pelleted (5 min at 400×g) and resuspended in PBS plus 1% ΔFBS. Cells were blocked with rat anti-mouse FcγIII/IIR mAb (BD Biosciences Pharmingen) in 1% ΔFBS in PBS and stained for 45 min at 4°C with fluorophore-conjugated Ab, washed, fixed with Fix Buffer (4% Paraformaldehyde (Electron Microscopy Sciences), 0.01% Tween-20 (Sigma) in PBS), washed, permeabilized with Perm Buffer (0.5% BSA (Sigma), 0.1% Triton-X100 (Sigma) in PBS), washed, stained overnight at RT, washed and then analyzed using an LSR II instrument with CellQuest (BD Biosciences) software. Analysis was performed using FlowJo software (version 8.73; Tree Star).
Freshly harvested osteoclast precursor cells were cultured with 20 ng/ml M-CSF for 3 days on a 15 cm Petri dish (Corning). Cells were removed with Versene and seeded at 8.5×104 cells/well on a 96 well plate with M-CSF to allow BM precursor to adhere. The following day (day 0), GST-RANKL was added to the osteoclast precursor cell culture in the presence or absence of pre-activated TcREG. T-cells were washed off (day 5) and the adherent cells were assayed for tartrate-resistant acid phosphatase activity using a fluorescent substrate, ELF-97 (Invitrogen), in accordance with the manufacturer’s protocol.
On day 0, mature osteoclast were plated at 8.5×104 cells/well on a 96 well plate alone or with pre-differentiated TcREG. Day 5, non-adherent cells were removed and remaining cells were counted and stained with FITC-conjugated Annexin-V (Biotium).
For in-situ differentiated TcREG, on day 0, mature osteoclast (5×105) were seeded on 24-well hydroxyapatite coated plates (Corning or BD Biosciences). Day 1, osteoclast were pulsed with SIINFEKL peptide for 4 h, washed, and then naïve OT-I T-cells were added. M-CSF and GST-RANKL were added every 48 h. Day 10, cells were removed with 10% bleach and pit area was photographed and quantified using NIH ImageJ.
For pre-differentiated TcREG, day 0, osteoclasts were seeded as above. Day 1 osteoclasts were pulsed with SIINFEKL peptide or no antigen for 4 h, washed, and then pre-differentiated TcREG were added. M-CSF and GST-RANKL were added every 48 h. On day 7, cells were removed with 10% bleach and pit area was photographed and quantified using NIH ImageJ.
For transwell assays, osteoclasts were plated as described above. Cells were allowed to adhere overnight, and media was replaced with 700 µl of complete T-cell media containing M-CSF and GST-RANKL in the bottom well. 5×105 TcREG were added to top insert in 300 µl. Cells were re-fed every 48 h with M-CSF and RANKL. Following 10 days of incubation, bottom wells were treated with bleach to remove cells, and pit area was quantified, as above.
Purification of TcREG from FoxP3eGFP Reporter Mice
To purify activated TcREG we activated osteoclasts in vivo by injecting the FoxP3eGFP mice with RANKL (1 mg/kg intraperitoneally). Two doses of RANKL were given intraperitoneally on consecutive days; this protocol is modified from , where three doses were administered. The mice were sacrificed 50 hours post first RANKL dose and bone marrow cells harvested as described in osteoclast generation section above. Magnetic beads (Miltenyi) were used to positively select CD8 T-cells. The eluted cells were stained with V450-conjugated CD3 (clone 17A2; eBioscience) and PE-conjugated CD8a antibodies and further purified by cell sorting on Aria instrument with FACS Diva software (BD Biosciences).
Antibody Neutralization Assay
Immature day two osteoclasts were lifted and 8.5×104 cells were seeded on 96-well hydroxyapatite coated plates (Corning). After overnight incubation, pre-differentiated TcREG (8.5×104) were added with neutralizing antibodies. M-CSF and GST-RANKL were added every 72 h. After additional six days, cells were removed with 10% hypochlorite, photographed and pit area was quantified using NIH ImageJ. The lowest concentration of antibody (see legend Fig. 5C) that gave maximum number of pits was determined from an antibody titration.
Actin Ring Assay
Mature osteoclast were plated at 3×103 cell/well on bovine bone slides or on plastic in a 48 well plate. Following overnight adherence, TcREG or naïve OT-I T-cells were added at a 1∶1 T-cell to osteoclast ratio. After a 24 h co-incubation, the non-adherent cells were removed; adherent cells were fixed (4% Paraformaldehyde (EMS), 0.2% Triton-X100 (Sigma) in PBS) for 10 minutes, washed thrice with PBS and then stained with phalloidin-Texas Red (Biotium) for 15 min. The cells were photographed and actin ring size was quantified using NIH ImageJ software.
RT-PCR and Quantitative Real-time PCR
Total RNA was purified from cell lysates following manufacturers instructions (Agilent technologies). For FoxP3, cDNA was generated (Invitrogen) and subsequently PCR amplified for 45 cycles. The reaction contained 2.5 mM MgCl2, 0.2 mM dNTPs. qRT-PCR for CTSK, TRAP and MMP-9 transcripts were performed on ABI7500 instrument using a one-step (Invitrogen) SYBR green kit for 40 cycles using input 1 ng total RNA. The data is expressed as 2ΔΔCt (relative quantity or RQ) by normalizing to β-actin expression between samples. The primer sequences used for analyses of RNA expression span at least one intron, are shown in Table 1.
All statistical analyses were performed with GraphPad Prism (version 5.0c). Wilcoxon or Student’s T test were used for determining statistical significance for osteoclast alone and osteoclast plus treatment as indicated in the Figure legends or in the methods described above.
We are grateful to Dr. Steve Teitelbaum for providing the GST-RANKL expression system. Dr. Deborah Novack is thanked for stimulating discussions and protocols. We thank Dr. John Tavis for providing duck HBV polymerase and antibodies. We acknowledge Sherri Koehm and Joy Eslick for processing flow cytometry samples.
Conceived and designed the experiments: RA. Performed the experiments: ZSB JRK MSP RA. Analyzed the data: ZSB JRK RA. Contributed reagents/materials/analysis tools: RD. Wrote the paper: ZSB RA.
- 1. Henriksen K, Neutzsky-Wulff AV, Bonewald LF, Karsdal MA (2009) Local communication on and within bone controls bone remodeling. Bone 44: 1026–1033.
- 2. Udagawa N, Takahashi N, Jimi E, Matsuzaki K, Tsurukai T, et al. (1999) Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand. Bone 25: 517–523.
- 3. Takami M, Woo JT, Nagai K (1999) Osteoblastic cells induce fusion and activation of osteoclasts through a mechanism independent of macrophage-colony-stimulating factor production. Cell Tissue Res 298: 327–334.
- 4. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, et al. (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20: 345–357.
- 5. Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, et al. (1999) Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 190: 1741–1754.
- 6. Arron JR, Choi Y (2000) Bone versus immune system. Nature 408: 535–536.
- 7. David JP (2007) Osteoimmunology: a view from the bone. Adv Immunol 95: 149–165.
- 8. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, et al. (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203: 2673–2682.
- 9. Takayanagi H (2005) Osteoimmunological insight into bone damage in rheumatoid arthritis. Mod Rheumatol 15: 225–231.
- 10. Taubman MA, Valverde P, Han X, Kawai T (2005) Immune response: the key to bone resorption in periodontal disease. J Periodontol 76: 2033–2041.
- 11. Teng YT (2006) Protective and destructive immunity in the periodontium: Part 2–T-cell-mediated immunity in the periodontium. J Dent Res 85: 209–219.
- 12. Theill LE, Boyle WJ, Penninger JM (2002) RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 20: 795–823.
- 13. Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, et al. (2006) Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 24: 33–63.
- 14. Mossetti G, Rendina D, De Filippo G, Viceconti R, Di Domenico G, et al. (2005) Interleukin-6 and osteoprotegerin systems in Paget’s disease of bone: relationship to risedronate treatment. Bone 36: 549–554.
- 15. Rodan GA, Martin TJ (2000) Therapeutic approaches to bone diseases. Science 289: 1508–1514.
- 16. Novack DV, Teitelbaum SL (2008) The osteoclast: friend or foe? Annu Rev Pathol 3: 457–484.
- 17. Pacifici R (2008) Estrogen deficiency, T cells and bone loss. Cell Immunol 252: 68–80.
- 18. Khattri R, Cox T, Yasayko SA, Ramsdell F (2003) An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 4: 337–342.
- 19. van der Vliet HJ, Nieuwenhuis EE (2007) IPEX as a result of mutations in FOXP3. Clin Dev Immunol 2007: 89017. 89017 p.
- 20. Schubert LA, Jeffery E, Zhang Y, Ramsdell F, Ziegler SF (2001) Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation. J Biol Chem 276: 37672–37679.
- 21. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, et al. (2001) Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 27: 68–73.
- 22. Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4: 330–336.
- 23. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057–1061.
- 24. Huter EN, Punkosdy GA, Glass DD, Cheng LI, Ward JM, et al. (2008) TGF-beta-induced FoxP3+ regulatory T cells rescue scurfy mice. Eur J Immunol 38: 1814–1821.
- 25. Zheng SG, Wang JH, Gray JD, Soucier H, Horwitz DA (2004) Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10. J Immunol 172: 5213–5221.
- 26. Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, et al. (1998) Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 10: 1969–1980.
- 27. Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6: 345–352.
- 28. Asseman C, Read S, Powrie F (2003) Colitogenic Th1 cells are present in the antigen-experienced T cell pool in normal mice: control by CD4+ regulatory T cells and IL-10. J Immunol 171: 971–978.
- 29. Li MO, Sanjabi S, Flavell RA (2006) Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 25: 455–471.
- 30. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA (2006) Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 24: 99–146.
- 31. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, et al. (2007) The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450: 566–569.
- 32. Paterson AM, Sharpe AH (2010) Taming tissue-specific T cells: CTLA-4 reins in self-reactive T cells. Nat Immunol 11: 109–111.
- 33. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ (2007) CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol 8: 1353–1362.
- 34. Shevach EM (2006) From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 25: 195–201.
- 35. Konya C, Goronzy JJ, Weyand CM (2009) Treating autoimmune disease by targeting CD8(+) T suppressor cells. Expert Opin Biol Ther 9: 951–965.
- 36. Suzuki M, Konya C, Goronzy JJ, Weyand CM (2008) Inhibitory CD8+ T cells in autoimmune disease. Hum Immunol 69: 781–789.
- 37. Waschbisch A, Schwab N, Ruck T, Stenner MP, Wiendl H (2010) FOXP3+ T regulatory cells in idiopathic inflammatory myopathies. J Neuroimmunol 225: 137–142.
- 38. Sharabi A, Mozes E (2008) The suppression of murine lupus by a tolerogenic peptide involves foxp3-expressing CD8 cells that are required for the optimal induction and function of foxp3-expressing CD4 cells. J Immunol 181: 3243–3251.
- 39. Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, et al. (2007) CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 13: 6947–6958.
- 40. Singh RP, La Cava A, Wong M, Ebling F, Hahn BH (2007) CD8+ T cell-mediated suppression of autoimmunity in a murine lupus model of peptide-induced immune tolerance depends on Foxp3 expression. J Immunol 178: 7649–7657.
- 41. Tsai S, Shameli A, Yamanouchi J, Clemente-Casares X, Wang J, et al. (2010) Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity 32: 568–580.
- 42. Kiesel J, Miller C, Abu-Amer Y, Aurora R (2007) Systems level analysis of osteoclastogenesis reveals intrinsic and extrinsic regulatory interactions. Dev Dyn 236: 2181–2197.
- 43. Li H, Hong S, Qian J, Zheng Y, Yang J, et al. (2010) Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells. Blood 116: 210–217.
- 44. Kiesel JR, Buchwald ZS, Aurora R (2009) Cross-presentation by osteoclasts induces FoxP3 in CD8+ T cells. J Immunol 182: 5477–5487.
- 45. Takayanagi H, Kim S, Taniguchi T (2002) Signaling crosstalk between RANKL and interferons in osteoclast differentiation. Arthritis Res 4: Suppl 3S227–232.
- 46. Fox SW, Chambers TJ (2000) Interferon-gamma directly inhibits TRANCE-induced osteoclastogenesis. Biochem Biophys Res Commun 276: 868–872.
- 47. van’t Hof RJ, Ralston SH (1997) Cytokine-induced nitric oxide inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast activity. J Bone Miner Res 12: 1797–1804.
- 48. Axmann R, Herman S, Zaiss M, Franz S, Polzer K, et al. (2008) CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis 67: 1603–1609.
- 49. Zaiss MM, Axmann R, Zwerina J, Polzer K, Guckel E, et al. (2007) Treg cells suppress osteoclast formation: A new link between the immune system and bone. Arthritis Rheum 56: 4104–4112.
- 50. Nagahama K, Aoki K, Nonaka K, Saito H, Takahashi M, et al. (2004) The deficiency of immunoregulatory receptor PD-1 causes mild osteopetrosis. Bone 35: 1059–1068.
- 51. Cheung J, Mak YT, Papaioannou S, Evans BA, Fogelman I, et al. (2003) Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. J Endocrinol 177: 423–433.
- 52. Haribhai D, Lin W, Relland LM, Truong N, Williams CB, et al. (2007) Regulatory T cells dynamically control the primary immune response to foreign antigen. J Immunol 178: 2961–2972.
- 53. Lin W, Haribhai D, Relland LM, Truong N, Carlson MR, et al. (2007) Regulatory T cell development in the absence of functional Foxp3. Nat Immunol 8: 359–368.
- 54. Chen W, Jin W, Hardegen N, Lei KJ, Li L, et al. (2003) Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198: 1875–1886.
- 55. Davidson TS, DiPaolo RJ, Andersson J, Shevach EM (2007) Cutting Edge: IL-2 is essential for TGF-beta-mediated induction of Foxp3+ T regulatory cells. J Immunol 178: 4022–4026.
- 56. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, et al. (2004) Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 172: 5149–5153.
- 57. Oursler MJ (1994) Osteoclast synthesis and secretion and activation of latent transforming growth factor beta. J Bone Miner Res 9: 443–452.
- 58. Bonewald LF, Oreffo RO, Lee CH, Park-Snyder S, Twardzik D, et al. (1997) Effects of retinol on activation of latent transforming growth factor-beta by isolated osteoclasts. Endocrinology 138: 657–666.
- 59. Centrella M, McCarthy TL, Canalis E (1989) Effects of transforming growth factors on bone cells. Connect Tissue Res 20: 267–275.
- 60. Dallas SL, Rosser JL, Mundy GR, Bonewald LF (2002) Proteolysis of latent transforming growth factor-beta (TGF-beta )-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem 277: 21352–21360.
- 61. Fuller K, Lean JM, Bayley KE, Wani MR, Chambers TJ (2000) A role for TGFbeta(1) in osteoclast differentiation and survival. J Cell Sci 113 (Pt 13): 2445–2453.
- 62. Filgueira L (2004) Fluorescence-based staining for tartrate-resistant acidic phosphatase (TRAP) in osteoclasts combined with other fluorescent dyes and protocols. J Histochem Cytochem 52: 411–414.
- 63. Kohara H, Kitaura H, Fujimura Y, Yoshimatsu M, Morita Y, et al. (2011) IFN-gamma directly inhibits TNF-alpha-induced osteoclastogenesis in vitro and in vivo and induces apoptosis mediated by Fas/Fas ligand interactions. Immunol Lett 137: 53–61.
- 64. Huang X, Yokota T, Iwata J, Chai Y (2011) Tgf-beta-mediated FasL-Fas-Caspase pathway is crucial during palatogenesis. J Dent Res 90: 981–987.
- 65. Zhang H, Hile KL, Asanuma H, Vanderbrink B, Franke EI, et al. (2011) IL-18 mediates proapoptotic signaling in renal tubular cells through a Fas ligand-dependent mechanism. Am J Physiol Renal Physiol 301: F171–178.
- 66. Novack DV, Faccio R (2011) Osteoclast motility: putting the brakes on bone resorption. Ageing Res Rev 10: 54–61.
- 67. Soysa NS, Alles N, Aoki K, Ohya K (2009) Three-dimensional characterization of osteoclast bone-resorbing activity in the resorption lacunae. J Med Dent Sci 56: 107–112.
- 68. Luxenburg C, Geblinger D, Klein E, Anderson K, Hanein D, et al. (2007) The architecture of the adhesive apparatus of cultured osteoclasts: from podosome formation to sealing zone assembly. PLoS One 2: e179.
- 69. Krause CD, Lunn CA, Izotova LS, Mirochnitchenko O, Kotenko SV, et al. (2000) Signaling by covalent heterodimers of interferon-gamma. Evidence for one-sided signaling in the active tetrameric receptor complex. J Biol Chem 275: 22995–23004.
- 70. Caetano-Lopes J, Canhao H, Fonseca JE (2009) Osteoimmunology–the hidden immune regulation of bone. Autoimmun Rev 8: 250–255.
- 71. Lorenzo J, Choi Y (2005) Osteoimmunology. Immunol Rev 208: 5–6.
- 72. Takayanagi H (2007) Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7: 292–304.
- 73. Aandahl EM, Torgersen KM, Tasken K (2008) CD8+ regulatory T cells-A distinct T-cell lineage or a transient T-cell phenotype? Hum Immunol 69: 696–699.
- 74. Ablamunits V, Herold KC (2008) Generation and function of human regulatory CD8+ T cells induced by a humanized OKT3 monoclonal antibody hOKT3gamma1 (Ala-Ala). Hum Immunol 69: 732–736.
- 75. Allez M, Brimnes J, Dotan I, Mayer L (2002) Expansion of CD8+ T cells with regulatory function after interaction with intestinal epithelial cells. Gastroenterology 123: 1516–1526.
- 76. Banham AH, Powrie FM, Suri-Payer E (2006) FOXP3+ regulatory T cells: Current controversies and future perspectives. Eur J Immunol 36: 2832–2836.
- 77. Brimnes J, Allez M, Dotan I, Shao L, Nakazawa A, et al. (2005) Defects in CD8+ regulatory T cells in the lamina propria of patients with inflammatory bowel disease. J Immunol 174: 5814–5822.
- 78. Colovai AI, Mirza M, Vlad G, Wang S, Ho E, et al. (2003) Regulatory CD8+CD28- T cells in heart transplant recipients. Hum Immunol 64: 31–37.
- 79. Correale J, Villa A (2010) Role of CD8+ CD25+ Foxp3+ regulatory T cells in multiple sclerosis. Ann Neurol 67: 625–638.
- 80. Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, et al. (2007) Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445: 771–775.
- 81. Jiang H, Chess L (2008) Qa-1/HLA-E-restricted regulatory CD8+ T cells and self-nonself discrimination: an essay on peripheral T-cell regulation. Hum Immunol 69: 721–727.
- 82. Kared H, Adle-Biassette H, Fois E, Masson A, Bach JF, et al. (2006) Jagged2-expressing hematopoietic progenitors promote regulatory T cell expansion in the periphery through notch signaling. Immunity 25: 823–834.
- 83. Kezuka T, Streilein JW (2000) In vitro generation of regulatory CD8+ T cells similar to those found in mice with anterior chamber-associated immune deviation. Invest Ophthalmol Vis Sci 41: 1803–1811.
- 84. Meloni F, Morosini M, Solari N, Passadore I, Nascimbene C, et al. (2006) Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol 67: 1–12.
- 85. Niederkorn JY (2008) Emerging concepts in CD8(+) T regulatory cells. Curr Opin Immunol 20: 327–331.
- 86. Shevach EM, DiPaolo RA, Andersson J, Zhao DM, Stephens GL, et al. (2006) The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol Rev 212: 60–73.
- 87. Stephens GL, Andersson J, Shevach EM (2007) Distinct subsets of FoxP3+ regulatory T cells participate in the control of immune responses. J Immunol 178: 6901–6911.
- 88. Mayer CT, Floess S, Baru AM, Lahl K, Huehn J, et al. (2011) CD8+ Foxp3+ T cells share developmental and phenotypic features with classical CD4+ Foxp3+ regulatory T cells but lack potent suppressive activity. Eur J Immunol 41: 716–725.
- 89. Sato K (2008) Th17 cells and rheumatoid arthritis–from the standpoint of osteoclast differentiation. Allergol Int 57: 109–114.
- 90. Corthay A (2009) How do regulatory T cells work? Scand J Immunol 70: 326–336.
- 91. Pillai MR, Collison LW, Wang X, Finkelstein D, Rehg JE, et al. (2011) The plasticity of regulatory T cell function. J Immunol 187: 4987–4997.
- 92. Martin TJ, Seeman E (2008) Bone remodelling: its local regulation and the emergence of bone fragility. Best Pract Res Clin Endocrinol Metab 22: 701–722.
- 93. Matsuo K, Irie N (2008) Osteoclast-osteoblast communication. Arch Biochem Biophys 473: 201–209.
- 94. Adams GB, Scadden DT (2006) The hematopoietic stem cell in its place. Nat Immunol 7: 333–337.
- 95. Arai F, Hirao A, Suda T (2005) Regulation of hematopoiesis and its interaction with stem cell niches. Int J Hematol 82: 371–376.
- 96. Badillo AT, Flake AW (2006) The regulatory role of stromal microenvironments in fetal hematopoietic ontogeny. Stem Cell Rev 2: 241–246.
- 97. Haylock DN, Nilsson SK (2005) Stem cell regulation by the hematopoietic stem cell niche. Cell Cycle 4: 1353–1355.
- 98. Kollet O, Dar A, Lapidot T (2007) The multiple roles of osteoclasts in host defense: bone remodeling and hematopoietic stem cell mobilization. Annu Rev Immunol 25: 51–69.
- 99. Kollet O, Dar A, Shivtiel S, Kalinkovich A, Lapid K, et al. (2006) Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med 12: 657–664.
- 100. Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L (1989) Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J Immunol 142: 1536–1541.
- 101. Tomimori Y, Mori K, Koide M, Nakamichi Y, Ninomiya T, et al. (2009) Evaluation of pharmaceuticals with a novel 50-hour animal model of bone loss. J Bone Miner Res 24: 1194–1205.